# How NAD+ comes up in studies and prescription care

NAD+ can come up in a discussion about food, a study of an oral ingredient, or a prescription for a particular preparation. Each setting uses the name for a different purpose. The distinction starts with what the preparation actually contains.

## What the name can refer to

Cells make NAD+ all the time. They use it when they release energy from food and in reactions that help maintain and repair cells. The body also makes it out of other substances. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors, meaning cells can use them as ingredients to build NAD+. The [comparison of NR and NMN](/nmn-vs-nr) shows where each enters that process.

Research articles and product descriptions sometimes use the term NAD+ broadly. In an article about a trial, the methods describe what the researchers gave people, such as NR by mouth or NAD+ as an infusion. In a description of a formulation, the ingredient name refers to what went into it. The route refers to how the substance enters the body. For example, an infusion delivers fluid into a vein, and a preparation taken by mouth passes through the digestive system. A shared name in a headline can conceal both distinctions.

## Where the evidence comes from

Controlled trials compare what happens with the substance being studied against a group or period used for comparison. The comparison helps separate the effect of the substance from changes that might happen over time anyway. For instance, in a [controlled trial of oral NR](https://pubmed.ncbi.nlm.nih.gov/31278280/), researchers found that the NR groups had higher whole-blood NAD+. That result describes a chemical reading after people took the ingredient by mouth.

Researchers in an [NAD+ infusion pilot](https://pubmed.ncbi.nlm.nih.gov/31572171/) tracked different things. Their blood and urine samples described changes over hours and helped show when the substance and its breakdown products could be found. It was an early study of how the body handled the infusion. A trial that measured long-term symptoms would need a different design and evidence gathered over a longer period.

## Three ways NAD+ comes up

1. Oral precursors such as NR and NMN appear in studies where the starting
   ingredient is taken by mouth. The [human trials reviewed in
   2025](https://pubmed.ncbi.nlm.nih.gov/41083806/) offer evidence on blood
   readings and a smaller set of measured changes in health or ability. The
   results depend on the exact ingredient, the participants and the outcome the
   researchers chose.
2. A research study can test how the body handles a substance or whether it
   changes a particular result. The published paper describes who took part, the
   form that was studied and the period of observation. That information gives
   the result its scope. A study of one form leaves the outcomes for other forms
   open.
3. People need a prescription to get a particular NAD+ preparation through
   Promise Peptides (mypromise.com), which serves patients only in the United
   States.

## How U.S. rules address compounding

[FDA's overview of compounding](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) describes how a medicine can be made to meet a particular treatment need. Section 503A covers patient-specific compounding under set conditions, including a valid prescription for an individual patient. Section 503B covers registered outsourcing facilities under a separate set of conditions. Compounded drugs are not FDA-approved. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.

The [FDA bulk-substances page](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) explains where the ingredient itself fits into 503A. The rules consider whether the ingredient has a relevant official standard, is a component of an approved drug, or appears on the applicable bulk-substances list. In FDA's interim policy, Category 2 refers to nominated ingredients for which FDA identified significant safety concerns. FDA tracks [withdrawn nominations separately](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks).

In its [October 30, 2026 notice](https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances), the U.S. Department of Health and Human Services announced a draft, nonbinding enforcement policy for state-licensed pharmacies, federal facilities and licensed physicians. It describes when the department does not intend to take action under specified 503A conditions, including a valid prescription for an individual patient. It applies to single active ingredients and names six peptides. They are BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. Its scope excludes NAD+, blends and 503B outsourcing facilities. The draft grants no FDA drug approval.

---

Cell fuel, heart studies

[Source notes and study links](/references)

These NAD+ articles cover published studies for general reading, without personal medical advice.
